Antiretroviral therapy and tuberculosis: does the regimen matter?

References

• Suthar AB, Lawn SD, del Amo J et al. Antiretroviral therapy for prevention of tuberculosis in adults with HIV: a systematic review and meta-analysis. PLoS Med. 9(7), e1001270 (2012).
   PubMed Web of Science ®Google Scholar
• Lawn SD, Wood R, De Cock KM, Kranzer K, Lewis JJ, Churchyard GJ. Antiretrovirals and isoniazid preventive therapy in the prevention of HIV-associated tuberculosis in settings with limited health-care resources. Lancet Infect. Dis. 10(7), 489–498 (2010).
   PubMed Web of Science ®Google Scholar
• Hermans SM, Manabe YC, Kiragga AN, Hoepelman AI, Lange JM, van Leth F. Risk of tuberculosis after antiretroviral treatment initiation: a comparison between efavirenz and nevirapine using inverse probability weighting. Antivir. Ther. 18(4), 615–622 (2013).
   PubMedGoogle Scholar
• Van Leth F, Phanuphak P, Ruxrungtham K et al. Comparison of first-line antiretroviral therapy with regimens including nevirapine, efavirenz, or both drugs, plus stavudine and lamivudine: a randomised open-label trial, the 2NN Study. Lancet 363(9417), 1253–1263 (2004).
   PubMed Web of Science ®Google Scholar
• MacArthur RD, Novak RM, Peng G et al. A comparison of three highly active antiretroviral treatment strategies consisting of non-nucleoside reverse transcriptase inhibitors, protease inhibitors, or both in the presence of nucleoside reverse transcriptase inhibitors as initial therapy (CPCRA 058 FIRST Study): a long-term randomised trial. Lancet 368(9553), 2125–2135 (2006).
   PubMed Web of Science ®Google Scholar
• Lockman S, Hughes M, Sawe F et al. Nevirapine- versus lopinavir/ritonavir-based initial therapy for HIV-1 infection among women in Africa: a randomized trial. PLoS Med. 9(6), e1001236 (2012).
   PubMedGoogle Scholar
• Riddler SA, Haubrich R, DiRienzo AG et al. Class-sparing regimens for initial treatment of HIV-1 infection. N. Engl. J. Med. 358(20), 2095–2106 (2008).
   PubMed Web of Science ®Google Scholar
• Squires K, Lazzarin A, Gatell JM et al. Comparison of once-daily atazanavir with efavirenz, each in combination with fixed-dose zidovudine and lamivudine, as initial therapy for patients infected with HIV. J. Acquir. Immune Defic. Syndr. 36(5), 1011–1019 (2004).
   PubMed Web of Science ®Google Scholar
• Soriano V, Arastéh K, Migrone H et al. Nevirapine versus atazanavir/ritonavir, each combined with tenofovir disoproxil fumarate/emtricitabine, in antiretroviral-naive HIV-1 patients: the ARTEN Trial. Antivir. Ther. 16(3), 339–348 (2011).
   PubMed Web of Science ®Google Scholar
• Molina J-M, Andrade-Villanueva J, Echevarria J et al. Once-daily atazanavir/ritonavir versus twice-daily lopinavir/ritonavir, each in combination with tenofovir and emtricitabine, for management of antiretroviral-naive HIV-1-infected patients: 48 week efficacy and safety results of the CASTLE study. Lancet 372(9639), 646–655 (2008).
   PubMed Web of Science ®Google Scholar
• Ortiz R, Dejesus E, Khanlou H et al. Efficacy and safety of once-daily darunavir/ritonavir versus lopinavir/ritonavir in treatment-naive HIV-1-infected patients at week 48. AIDS 22(12), 1389–1397 (2008).
   PubMed Web of Science ®Google Scholar
• André P, Groettrup M, Klenerman P et al. An inhibitor of HIV-1 protease modulates proteasome activity, antigen presentation, and T cell responses. Proc. Natl Acad. Sci. USA 95(22), 13120–13124 (1998).
   PubMed Web of Science ®Google Scholar
• Piccinini M, Rinaudo MT, Anselmino A et al. The HIV protease inhibitors nelfinavir and saquinavir, but not a variety of HIV reverse transcriptase inhibitors, adversely affect human proteasome function. Antivir. Ther. 10(2), 215–223 (2005).
   PubMed Web of Science ®Google Scholar
• Lamichhane G. Novel targets in M. tuberculosis: search for new drugs. Trends Mol. Med. doi:10.1016/j.molmed.2010.10.004 (2010) ( Epub ahead of print).
   PubMedGoogle Scholar
• Nnoaham KE, Clarke A. Low serum vitamin D levels and tuberculosis: a systematic review and meta-analysis. Int. J. Epidemiol. 37(1), 113–119 (2008).
   PubMed Web of Science ®Google Scholar
• Allavena C, Delpierre C, Cuzin L et al. High frequency of vitamin D deficiency in HIV-infected patients: effects of HIV-related factors and antiretroviral drugs. J. Antimicrob. Chemother. 67(9), 2222–2230 (2012).
   PubMedGoogle Scholar
• Akolo C, Adetifa I, Shepperd S, Volmink J. Treatment of latent tuberculosis infection in HIV infected persons. Cochrane Database Syst. Rev. (1), CD000171 (2010).
   PubMed Web of Science ®Google Scholar
• World Health Organization. Global Tuberculosis Report 2012. WHO, Geneva, Switzerland (2012).
   Google Scholar
• ART-LINC Collaboration of International Databases to Evaluate AIDS (IeDEA); Keiser O, Anastos K, Schechter M et al. Antiretroviral therapy in resource-limited settings 1996 to 2006: patient characteristics, treatment regimens and monitoring in sub-Saharan Africa, Asia and Latin America. Trop. Med. Int. Health 13(7), 870–879 (2008).
   PubMedGoogle Scholar
• Lesko CR, Cole SR, Zinski A, Poole C, Mugavero MJ. A systematic review and meta-regression of temporal trends in adult CD4+ cell count at presentation to HIV care, 1992–2011. Clin. Infect. Dis. 57(7), 1027–1037(2013).
   PubMed Web of Science ®Google Scholar